PRMT1 and Miyoshi myopathy: PRMT1 is the most prominently expressed PRMT in MM cell lines and primary malignant plasma cells from MM patients, with significantly elevated levels observed in relapsed/refractory patients and linked to poor prognosis, highlighting its potential role in disease progression and treatment resistance [34, 35].